-
Je něco špatně v tomto záznamu ?
Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience
M. Matysková Kubišová, S. Dusilová Sulková, P. Moučka, A. Pokorná, M. Heislerová, I. Guňka, P. Navrátil, J. Pacovský, A. Malá, R. Šafránek
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2022
PubMed Central
od 2022
Medline Complete (EBSCOhost)
od 2004-05-01
ROAD: Directory of Open Access Scholarly Resources
od 1988
PubMed
39391264
DOI
10.3389/ti.2024.12920
Knihovny.cz E-zdroje
- MeSH
- antivirové látky terapeutické užití MeSH
- COVID-19 * komplikace MeSH
- dospělí MeSH
- imunosupresiva * terapeutické užití MeSH
- kreatinin krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- pacienti ambulantní MeSH
- rejekce štěpu MeSH
- retrospektivní studie MeSH
- SARS-CoV-2 MeSH
- senioři MeSH
- transplantace ledvin * škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Patients undergoing kidney transplant are at risk of severe COVID-19. Our single-center retrospective analysis evaluated the outcomes of kidney transplant outpatients with COVID-19 who were managed with reduced immunosuppression and treatment with molnupiravir. Between January 2022 and May 2023, we included 93 patients (62 men, average age 56 years), serum creatinine 127 (101-153) μmol/L. Molnupiravir was administered, and immunosuppressive therapy was reduced immediately following the confirmation of SARS-CoV-2 infection by PCR, which was 2 (1-3) days after the onset of symptoms. Only three (3.2%) patients required hospitalization, and one patient died. Acute kidney injury was observed in two patients. During the follow-up period of 19 (15-22) months, there was no significant increase in proteinuria, no acute or new chronic graft rejection, and kidney graft function remained stable; serum creatinine was 124 (106-159) μmol/L post-COVID-19 infection and 128 (101-161) μmol/L at the end of the follow-up period. Our results demonstrate that early initiation of molnupiravir treatment combined with a temporary reduction in immunosuppressive therapy results in favorable clinical outcomes in patients with COVID-19, with preservation of good graft function and no episodes of graft rejection.
Department of Nephrology University Hospital Hradec Kralove Hradec Králové Czechia
Department of Surgery University Hospital Hradec Kralove Hradec Králové Czechia
Department of Urology University Hospital Hradec Kralove Hradec Králové Czechia
Hospital Pharmacy University Hospital Hradec Kralove Hradec Králové Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004107
- 003
- CZ-PrNML
- 005
- 20250206105132.0
- 007
- ta
- 008
- 250121e20240926sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/ti.2024.12920 $2 doi
- 035 __
- $a (PubMed)39391264
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Matysková Kubišová, Michaela $u Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 245 10
- $a Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience / $c M. Matysková Kubišová, S. Dusilová Sulková, P. Moučka, A. Pokorná, M. Heislerová, I. Guňka, P. Navrátil, J. Pacovský, A. Malá, R. Šafránek
- 520 9_
- $a Patients undergoing kidney transplant are at risk of severe COVID-19. Our single-center retrospective analysis evaluated the outcomes of kidney transplant outpatients with COVID-19 who were managed with reduced immunosuppression and treatment with molnupiravir. Between January 2022 and May 2023, we included 93 patients (62 men, average age 56 years), serum creatinine 127 (101-153) μmol/L. Molnupiravir was administered, and immunosuppressive therapy was reduced immediately following the confirmation of SARS-CoV-2 infection by PCR, which was 2 (1-3) days after the onset of symptoms. Only three (3.2%) patients required hospitalization, and one patient died. Acute kidney injury was observed in two patients. During the follow-up period of 19 (15-22) months, there was no significant increase in proteinuria, no acute or new chronic graft rejection, and kidney graft function remained stable; serum creatinine was 124 (106-159) μmol/L post-COVID-19 infection and 128 (101-161) μmol/L at the end of the follow-up period. Our results demonstrate that early initiation of molnupiravir treatment combined with a temporary reduction in immunosuppressive therapy results in favorable clinical outcomes in patients with COVID-19, with preservation of good graft function and no episodes of graft rejection.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a COVID-19 $x komplikace $7 D000086382
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a rejekce štěpu $7 D006084
- 650 _2
- $a antivirové látky $x terapeutické užití $7 D000998
- 650 _2
- $a pacienti ambulantní $7 D010045
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a kreatinin $x krev $7 D003404
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dusilová Sulková, Sylvie $u Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Moučka, Petr $u Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Pokorná, Anita $u Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Heislerová, Marcela $u Hospital Pharmacy, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Guňka, Igor $u Department of Surgery, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Navrátil, Pavel $u Department of Urology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Pacovský, Jaroslav $u Department of Urology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Malá, Alena $u Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 700 1_
- $a Šafránek, Roman $u Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia
- 773 0_
- $w MED00004553 $t Transplant international $x 1432-2277 $g Roč. 37 (20240926), s. 12920
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39391264 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105127 $b ABA008
- 999 __
- $a ok $b bmc $g 2263700 $s 1240114
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 37 $c - $d 12920 $e 20240926 $i 1432-2277 $m Transplant international $n Transpl Int $x MED00004553
- LZP __
- $a Pubmed-20250121